Buprenorphine without theater.

The X-waiver is gone. As of the Mainstreaming Addiction Treatment Act in late 2022, any DEA-registered prescriber can write buprenorphine for opioid use disorder. There is no separate license. There is no patient cap. There is no separate course (the eight hours of training are now folded into ordinary DEA registration renewal). The barrier that produced two decades of bottlenecked treatment in the United States — and that produced a generation of clinicians who simply did not consider OUD treatment to be primary-care work — has been dismantled.

And yet. The practical experience of trying to start someone on buprenorphine in a community primary-care office in 2026 is still, for most clinicians, an episode of theater. There is the urine drug screen at the front, the abstinence period and the COWS scoring, the carefully-staged in-office induction, the fear of precipitated withdrawal, the documented behavioral contract, the requirement of concurrent counseling, the threats of discharge for return-to-use. Every step of this theater has a defensible past. Almost none of it survives current evidence on its merits.

The medication is the framework

The single most consequential intervention in opioid use disorder is buprenorphine. The single most consequential thing the practice can do for a patient with OUD is to start it and keep them on it. The Cochrane review on buprenorphine maintenance versus placebo^[1] shows a substantial effect of medication on retention in treatment and on illicit opioid use; the literature on counseling-with-MOUD versus MOUD-without-counseling is, in most analyses, undecided^[2]. The medication, plain, is the framework. Counseling is an option for patients who want it. Therapy is an option for patients who want it. They are not gates.

If the medication is the framework, what does the rest of the encounter consist of? Logistics. The induction protocol. The dispensing. The state PMP rules. The DEA paperwork. The pharmacy faxes. Naloxone co-prescribing. The specific local availability of a dispensing pharmacy that stocks the formulation in a quantity sufficient to last the patient until next visit. That is most of the work, and almost none of it is clinically interesting. It is the kind of work that benefits from a small, accountable practice that knows the names of the pharmacists and the area code of the state PMP.

Induction has changed

The reason most primary-care clinicians know about buprenorphine and don't prescribe it is that, in the early 2010s, induction failed often enough that practices stopped trying. The induction protocol of that era — wait for the patient to be in mild-to-moderate withdrawal (COWS 8–12) before the first dose — worked when the U.S. illicit opioid supply was heroin and prescription pills. It works very poorly when the supply is fentanyl-pressed counterfeits.

The reason: fentanyl's pharmacokinetics. Fentanyl is highly lipophilic, accumulates in adipose tissue, and continues to release into the bloodstream for days after the last use. A patient with significant fentanyl on board who takes a 4-mg buprenorphine dose can experience precipitated withdrawal — the buprenorphine is a partial agonist with high mu-receptor affinity, and it displaces the fentanyl while only partially activating the receptor. The result is a withdrawal storm worse than the one the patient came in to avoid. We saw it. We caused it. We learned.

The current default in our practice, and increasingly the default in the literature, is the low-dose home induction sometimes called the Bernese method^[3]. The patient continues their existing opioid use. They start buprenorphine at 0.5 mg and double the daily dose over five to seven days, eventually crossing over to a full therapeutic dose without an abstinence period. The patient does not need to be in withdrawal at any point; they do not need to "white-knuckle" the gap. Case log 004 on the splits board is a worked example.

The urine drug screen, demoted

I have stopped using the urine drug screen as a precondition for treatment. I use it as one piece of clinical information among several, when it would change a clinical decision, and not as a behavioral lever. The patient who tests positive for fentanyl two weeks into treatment is a patient who is having a hard week, not a patient who has failed the program. The patient who tests positive for cocaine has not lost their right to buprenorphine. The patient who tests negative for buprenorphine when they should be positive for it is a patient I want to talk to about whether the medication is working — not a patient I'm trying to catch.

The discharge-for-return-to-use practice, which used to be widespread in OUD treatment, has been retired by every major framework I know — the SAMHSA TIP-63, the NIDA guidance, the Boston Medical Center protocols, the Yale model. A return to use is a clinical event, not a contractual breach. We don't discharge for clinical events. We re-engage.

What's still hard

What is still hard, on a practical day-to-day basis, in 2026: pharmacy access. There are independent pharmacies in greater Duluth that stock buprenorphine reliably and that have a working relationship with our practice. There are chain pharmacies that ration their stocks of buprenorphine because of fear of regulatory scrutiny^[4], and that produce ten-day stockouts at unpredictable intervals. The single most useful thing a practice can do for its OUD patients is keep a current list of pharmacies that have buprenorphine on the shelf. We update ours weekly. Members can see it; we publish it on the patient portal.

Also still hard: stigma in adjacent settings. Members on buprenorphine who are admitted to the hospital for unrelated indications have, multiple times, had their buprenorphine held at admission "to clarify the case," resulting in a withdrawal episode they did not need to have. We send a one-page letter with the member, signed, that names the medication, the dose, the indication, and our cell number. The letter does not always work. We send it anyway.

What it means to do this in primary care

The argument for treating OUD in primary care is the same argument as for treating any other chronic illness in primary care: continuity. The patient who has known their primary clinician for three years has, at the start of any treatment conversation, more relevant context than any specialist they could be referred to. The OUD is the same: the recovery arc is long, the relapses are normal, and the medication is the chronic management of a chronic disease.

I want, for what it's worth, to retire the entire framing of "addiction medicine" as a separate specialty. There are addiction-medicine specialists, and they do excellent work, especially in the harder corners of severe polysubstance use disorder and complex pain-and-OUD overlap. But the wide majority of buprenorphine prescriptions in this country could be written by primary care, in primary care, and the patients would do better. We have the data on this. We have for a decade. The bottleneck has been the X-waiver, and the X-waiver is gone.

The chronograph metaphor for this lane: the medication is the timing. Once the timing is right, what was a withdrawal storm becomes a quiet morning. The rest is logistics.

— SN